Can the right dosimetry approach turn palliative Y90 into a curative therapy? In this episode of the BackTable 2026 HCC Creator Weekend™, Interventional oncologists Dr. Riad Salem, Dr. Nima Kokabi, and Dr. Zach Berman examine modern Y90 dosimetry, from the decline of body-surface-area calculations to newer strategies that tailor treatment intensity to tumor burden, liver reserve, and clinical intent.
Get the BackTable app
https://www.backtable.com/app
This podcast is supported by an educational grant from Sirtex and Boston Scientific.
00:00 - Introduction
03:16 - MIRD and Dosing Considerations
06:20 - BSA Is Dead
09:26 - Early Stage Segmentectomy
13:04 - Sphere Density Questions
18:12 - CPN as the Goal
18:41 - BCLC B Multifocal Strategy
22:56 - Radiation Lobectomy Explained
25:49 - Surgery and Adhesions
28:59 - Advanced PVT Patients
30:22 - Dosisphere and Biomarkers
34:29 - Wrap Up
The doctors discuss how to choose how much radiation treatment to give and why “activity” (what you order) is different from “dose” (what tissue receives). The episode goes on to compare one-area calculations with more nuanced methods that distinguish tumor from healthy tissue, and explains why advanced 3D planning is often simpler after treatment than before. The discussion also covers treatment goals for various clinical scenarios, such as when to aim for complete ablation versus palliation, managing radiation lobectomy, and tailoring therapy in cases with portal vein tumor thrombus. The episode concludes with insights on how imaging informs treatment intensity and how local and systemic therapies work together in the latest Y90 approaches.
Combination treatment with transarterial chemoembolization, radiotherapy, and hyperthermia (CERT) for hepatocellular carcinoma with portal vein tumor thrombosis: Final results of a prospective phase II trial
https://pmc.ncbi.nlm.nih.gov/articles/PMC5581058/
A global evaluation of advanced dosimetry in transarterial radioembolization of hepatocellular carcinoma with Yttrium-90: the TARGET study
https://pubmed.ncbi.nlm.nih.gov/35394152/
Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma
https://pubmed.ncbi.nlm.nih.gov/27575820/
Long-Term Overall Survival After Selective Internal Radiation Therapy for Locally Advanced Hepatocellular Carcinomas: Updated Analysis of DOSISPHERE-01 Trial
https://jnm.snmjournals.org/content/early/2024/01/10/jnumed.123.266211
BackTable Vascular & Interventional (VI) is the go-to podcast for interventional radiologists, vascular surgeons, and interventional cardiologists.
Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty.
► https://www.backtable.com/app